Immunocore Holdings PLC (fra:6YG) Share Price

Company Profile

Business description
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Contact
92 Park Drive
Milton Park
AbingdonOxfordshireOX14 4RY
GBR
T: +44 1235438600
E: [email protected]
https://www.immunocore.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
493

Recommended

Our view on the potential acquisition.

Shaun Ler | 18 March 2025

4 factors that led to the incredible returns of Philip Morris.

Shani Jayamanne | 17 March 2025

These undervalued stocks of high-quality companies could be attractive investments today.

Margaret Giles | 17 March 2025

Index	Last price	Change	% Change
All Ordinaries	8,089.90	7.80	0.10%
CAC 40	8,114.57	40.59	0.50%
DAX 40	23,393.23	238.66	1.03%
Dow JONES (US)	41,472.25	369.38	-0.88%
FTSE 100	8,705.23	24.94	0.29%
HKSE	24,740.57	595.00	2.46%
NASDAQ	17,498.52	310.15	-1.74%
Nikkei 225	37,845.42	448.90	1.20%
NZX 50 Index	12,076.85	89.29	-0.73%
S&P 500	5,607.63	67.49	-1.19%
S&P/ASX 200	7,860.40	6.30	0.08%
SSE Composite Index	3,429.76	3.63	0.11%